When it comes to CBD, high bioavailability is the pot of gold at the end of the rainbow. Everyone’s chasing it, but Rapid Therapeutic Science Laboratories (RTSL), an emerging biotech firm, is harnessing one of the more effective (and safe) means of achieving it. Namely, the CBD metered dose inhaler.
First, a bit of background. Bioavailability refers to the amount of a substance (like CBD) that makes it into your system after you take it. With CBD, the method of taking the substance has an enormous impact on how much ends up in your bloodstream.
For example, by definition, if you take a medication via an IV, you have 100% bioavailability. But since that option isn’t available to the casual CBD consumer, we have to settle for lower absorption rates. Sometimes much lower.
For those serious about bioavailability, vaping (or smoking) cannabis extracts have long been the best option. But as we’ve seen in recent years, both of these methods can come with health risks that many people don’t want to take.
RTSI is targeting these CBD consumers (and the $5 billion current vape market they represent) with an FDA-approved delivery mechanism that provides 98% bioavailability.
The technology the company is utilizing isn’t itself new. In fact, most people with asthma will be very familiar with the metered dose inhaler (MDI). It uses aerosol technology to propel medication directly into the bloodstream via the lungs – without the use of heat or dangerous ingredients.
This isn’t the coolest looking way to take CBD. It looks just like any other pharmaceutical inhaler (which could be a plus for those for whom discretion is important).
Also, this technology doesn’t exactly come cheap. The 500mg inhaler comes to about .18 per milligram CBD, which is definitely on the high end of CBD prices.
RTSL markets its Rxoid MDI products directly to pharmacies and physicians who treat GAD, PTSD and other stress and anxiety disorders.
But with 98% bioavailability, a very small amount of CBD would go a much longer way than CBD taken sublingually or otherwise ingested. This essentially outweighs the higher cost by quite a bit.
And the company manufactures these MDIs using Current Good Manufacturing Practice (cGMP) that are mandated by the FDA with respect to the manufacture of all drugs and medical devices.
There’s also another possible benefit to aerosolized CBD (with heavy emphasis on “possible”). Researchers at the University of Lethbridge have found that high CBD strains of cannabis may play a role in reducing a type of receptor that enables Covid-19 to make itself at home in the human body.
These receptors hang out in the mouth and throat, but also in the lungs. Again, a lot more research is needed here, but researchers hypothesized that products that could deliver the substance to these areas could help protect a person from contracting the illness even after coming into contact with the virus.
Whether or not clinical trials bear out the hypothesis, RTSI is in a good position to benefit from people looking for a reliable, safe, and highly bioavailable method of taking CBD.
Potential consumers should keep in mind that there’s a bit of a learning curve when getting started with an MDI. Anyone who’s had to use one for their asthma can tell you that it will take a few attempts before you figure out how to inhale the optimal amount directly into your lungs.
The idea seems to be taking off though. In a recent press release, RTSI announced a 100,000 unit wholesale order for these inhalers.
According to company chairman and CEO, Donal R. Schmidt, Jr., Esq., “Our Rxoid CBD Inhalers are currently being sold through doctors’ offices and in pharmacies across the United States and we are extremely pleased about our products’ acceptance throughout the medical community.”